Literature DB >> 8517427

Effects of nadolol on hemodynamic and hemostatic responses to potential mental and physical triggers of myocardial infarction in subjects with mild systemic hypertension.

A H Jimenez1, G H Tofler, X Chen, M E Stubbs, H S Solomon, J E Muller.   

Abstract

Although beta-adrenergic blocking agents are known to reduce the risk of myocardial infarction, the mechanism of this protective effect is not well understood. The recent demonstration that beta blockers selectively blunt the increased morning risk of myocardial infarction suggests that these agents block the pathophysiologic consequences of stressors concentrated in the morning. We determined the effect of nadolol on the hemodynamic and hemostatic responses to mental stress and isometric exertion (handgrip), 2 potential triggers of infarction. The study was conducted in 15 subjects with mild systemic hypertension, using a placebo-controlled, double-blind, crossover design. Nadolol reduced systolic pressure and heart rate after mental stress. Poststress systolic pressure was 139 +/- 4 mm Hg during therapy with nadolol versus 161 +/- 4 mm Hg during placebo administration (p < 0.05). Heart rate increased to 61 +/- 2 during nadolol therapy versus 89 +/- 5 beats/min during placebo therapy (p < 0.05). The systolic pressure increase was similar during therapy with nadolol and placebo (29 +/- 2 vs 33 +/- 2 beats/min, p = NS); however, heart rate increase was less during nadolol therapy (4 +/- 1 vs 12 +/- 4 vs beats/min, p < 0.01). The responses to handgrip and their modification during nadolol therapy were similar to those observed after mental stress. Neither platelet aggregability nor fibrinolytic potential was altered by nadolol. Thus, nadolol modified hemodynamic indexes without altering the hemostatic indexes measured. This hemodynamic effect may contribute to the decrease in morning cardiovascular events by beta-adrenergic blockers and their well-documented cardioprotective effect.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8517427     DOI: 10.1016/0002-9149(93)90217-z

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  7 in total

Review 1.  Chronobiological considerations for exercise and heart disease.

Authors:  Greg Atkinson; Barry Drust; Keith George; Thomas Reilly; Jim Waterhouse
Journal:  Sports Med       Date:  2006       Impact factor: 11.136

2.  The effects of nebivolol on fibrinolytic parameters in mild and moderate hypertensive patients.

Authors:  Bahman Tarighi; Turhan Kurum; Muzaffer Demir; Sen Nur Azcan
Journal:  Can J Cardiol       Date:  2007-06       Impact factor: 5.223

3.  Bioequivalence of a highly variable drug: an experience with nadolol.

Authors:  R G Buice; V S Subramanian; K L Duchin; S Uko-Nne
Journal:  Pharm Res       Date:  1996-07       Impact factor: 4.200

4.  Effect of β-blockers on triggering of symptomatic atrial fibrillation by anger or stress.

Authors:  Rachel Lampert; Matthew M Burg; Larry D Jamner; James Dziura; Cynthia Brandt; Fangyong Li; Theresa Donovan; Robert Soufer
Journal:  Heart Rhythm       Date:  2019-06-03       Impact factor: 6.343

5.  Prolonged platelet activation in individuals with elevated blood pressure in response to a moderate exercise challenge.

Authors:  Suzi Hong; Karen A Adler; Roland Von Känel; Judy Nordberg; Michael G Ziegler; Paul J Mills
Journal:  Psychophysiology       Date:  2009-01-26       Impact factor: 4.016

6.  Circadian variation in the circulatory responses to exercise: relevance to the morning peaks in strokes and cardiac events.

Authors:  Greg Atkinson; Helen Jones; Philip N Ainslie
Journal:  Eur J Appl Physiol       Date:  2009-10-14       Impact factor: 3.078

7.  The long-term effects of metoprolol and epanolol on tissue-type plasminogen activator and plasminogen activator inhibitor 1 in patients with ischaemic heart disease.

Authors:  R A Wright; A M Perrie; F Stenhouse; K G Alberti; R A Riemersma; I R MacGregor; N A Boon
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.